

Scandion Oncology Newsletter 27 January, 2020

Scandion Oncology's first clinical phase 2 protocol will test SCO-101 in combination with the two chemotherapeutic drugs 5-Fluorouracil and Irinotecan (FOLFIRI) in metastatic colorectal cancer patients with FOLFIRI resistant disease. The Department of Oncology at Herlev-Gentofte Hospital in Copenhagen is the primary study site for the trial. As soon as possible, the Department of Oncology, Aalborg Hospital, Aalborg will start recruiting additional patients to the first part of the study. More study sites will be opened for the second part of the study, where it is primarily the anti-cancer effects of SCO-101 that are investigated.

As previously announced, we obtained approvals from the Danish Medicines Agency and the Ethics Committee late 2019. In addition, we have concluded all the additional paperwork including the agreements with the hospital administrations. Thus, we are now ready to enroll the first patients. It is unfortunate that the administrative procedures have taken so long time, but it is important for Scandion Oncology to strictly adhere to all local as well as national and international regulations.

Since almost all metastatic colorectal cancer patients who receive chemotherapy eventually experience disease recurrence, and since we annually in Denmark have more than 1800 new cases of metastatic colorectal cancer, SCO-101 has created a lot of interest and hope among patients and physicians. Thus, we have already experienced a high degree of interest in participating in our phase 2 clinical trial.

During this last month Scandion Oncology has initiated design of the clinical study protocol investigating SCO-101 in combination with chemotherapy for the treatment of pancreatic cancer. Pancreatic cancer patients have a very poor prognosis and almost no patients will reach 3rd line treatment. We propose to add SCO-101 to standard chemotherapy already at the first treatment of the patient with an aim to eradicate any preexisting or developing drug resistant cancer cells. We see this study as a first step to move SCO-101 treatment in combination with chemotherapy to adjuvant treatment, which is the very first systemic cancer treatment to be given to a newly diagnosed cancer patient. If successful, this could change the market potential of SCO-101 from blockbuster to multi blockbuster potential.

Kind regards



Nils Brünner, MD, Professor
CEO, Scandion Oncology

For further information regarding Scandion Oncology, please contact:

Nils Brünner, CEO

Phone: +45 26 14 47 08

E-mail: nb@scandiononcology.com